BiotechTube

Bazedoxifene/Conjugated Estrogen

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vasomotor Symptoms Associated With Menopause

Conditions

Vasomotor Symptoms Associated With Menopause

Trial Timeline

Oct 1, 2005 → Feb 1, 2007

NCT ID
NCT00234819

About Bazedoxifene/Conjugated Estrogen

Bazedoxifene/Conjugated Estrogen is a phase 3 stage product being developed by Pfizer for Vasomotor Symptoms Associated With Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00234819. Target conditions include Vasomotor Symptoms Associated With Menopause.

What happened to similar drugs?

1 of 13 similar drugs in Vasomotor Symptoms Associated With Menopause were approved

Approved (1) Terminated (0) Active (12)
✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
🔄fezolinetant + placeboAstellas PharmaPhase 3
🔄DVS-233 SRPfizerPhase 3
🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
🔄Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00238732Phase 3Completed
NCT00234819Phase 3Completed

Competing Products

20 competing products in Vasomotor Symptoms Associated With Menopause

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
40
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
35
esomeprazole + placeboAstraZenecaPre-clinical
26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mgMerckPhase 2
27
Erenumab + PlaceboAmgenPhase 1
29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
43
DVS-233 SRPfizerPhase 3
40
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
40
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
40
Treatment A + Treatment B + Treatment CBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 3
41
Elinzanetant (BAY3427080) treatment A + Elinzanetant (BAY3427080) treatment BBayerPhase 1
26
Elinzanetant (BAY3427080)BayerPhase 1
26
Moxifloxacin + Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26
Elinzanetant (BAY3427080) + Dabigatran etexilateBayerPhase 1
26
Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg + Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mgBayerPhase 3
37
BAY3427080BayerPhase 1
26
Elinzanetant (BAY3427080) + RosuvastatinBayerPhase 1
26